SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of Dehydrated Alcohol Injection, USP in the United States as a therapeutic generic equivalent of Ablysinol®, which ended its market exclusivity in June 2025. Dehydrated Alcohol Injection is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopa